TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total dosage of propofol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of nosocomial S. aureus infections
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma control questionnaire (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Timed Up and Go scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Degree of agreement between TD-CO and ED-CO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean eyebrow hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eyebrow hair diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesional score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Worries
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceptions of Insulin Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in major medical morbidities of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved neurodevelopmental functioning at 2 wCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved neurobehavioural functioning at 9 mCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ability to cope with stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling more relaxed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ability to carry out everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 5-year crude survival rate
Endpoint domain: Mortality/survival
Primary endpoint: change in depressive symptoms at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: peak blood alcohol concentration (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: related problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of days from onset to remission of nystagmus and vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (BP) goal reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ss-IGA score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hf-PGA score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: f-PGA score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impulsive/careless problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: positive attitude toward illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety characteristics scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rotavirus-induced gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hypoglycemia during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of headache-free days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour post-dose trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in total Genant‐modified Sharp score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quitting behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lower Back Pain (LBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCD14 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rate of upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hyponatremia correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-erosion microhardness values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gastric acid inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery time to glucose level ≥3.9 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time during naming of trained items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip BMD increase at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar spine BMD increase at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip BMD increase at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of anagen follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sebum casual level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful tourniquet placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC(0‐12,ss) for tramadol and acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of overweight in patients with functional constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically meaningful cognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corticosteroid resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C‐reactive protein normalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: MSPEV during the second Dix-Hallpike test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gag p24 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gag p15 response increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum phylloquinone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Undercarboxylated osteocalcin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: APA times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FES score
Endpoint domain: Life impact
Endpoint subdomain: Fear of falling
Primary endpoint: decrease of ischemia zone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lower pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower consumption of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher cosmetic satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gingival margin microleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of shared decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived importance of shared decision-making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: competence in shared decision-making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average BP perturbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average HR responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recognition of positive facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed in responding to positive self-relevant personality adjectives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory for positive information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: General Perceived Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NRS values at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrent infections
Endpoint domain: Adverse events/effects
Primary endpoint: Severe adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sustained virological response (SVR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants experiencing a fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute G2+ GI/GU toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: late G2+ GI toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IL-1 receptor antagonist (IL-1Ra)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declining body fat mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and course of NAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducible pocket depth measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood-smear negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: polymerase chain reaction-negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: delayed patent parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Healing rates of episiotomy wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correct understanding of test performance accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: OQ-45 total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean medical cost per SCS patient over 24 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modified Behavioral Pain Scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSP72 band lengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for indomethacin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall survival (OS) rate at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Overall failure-free survival rate at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival rate at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Esthetics evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inter-rater reliability of the total HDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral fat area/subcutaneous fat area ratio (VSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral fat area/thigh muscle area ratio (VMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: long-term cosmetic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chemotherapy dose delays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vascular normalization index (VNI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lymphatic vessel density (D2-40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Chair stand times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-m walking speeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviation of nasal septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations of the form of the middle nasal chonha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of agger nasi cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Variation in oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue compressibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased gun violence involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C (max) exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory follow-up colposcopy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in addressing depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in addressing substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in addressing stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: insight into illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Median values of intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentages of time with pH>4 for 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of acute renal rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: use of oral hypoglycemic agents
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Flow-mediated dilation (FMD) of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Carotid-femoral pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Kinesiophobia reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of perinatal death
Endpoint domain: Mortality/survival
Primary endpoint: CSF glycine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adolescent anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adolescent depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rear-foot FPI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpriming cervical width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHF-related readmission charges
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: CHF-related ED visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient satisfaction with tele-prehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of time that the glucose level was within the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume overload
Endpoint domain: Adverse events/effects
Primary endpoint: Attention and vigilance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-operative hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: adhesion of leiomyomas to the uterine wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: changes in uterine artery circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Median total symptom score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complications requiring antibiotic use
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance rate
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean change in yellowness (delta b*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in brightness (delta L*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure (EE) during overfeeding treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain rating on MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MVC force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG amplitude during MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attention domain improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visuospatial domain improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevention of increases in ABP postintubation >10% above baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for a nap
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Circulating phenotypic lymphocyte markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mitogen-stimulated cytokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Retention at 24 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-concordant UAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Morning cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycated hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FBF-response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 2-year incidence of a combined endpoint composed of death, cardiovascular hospitalizations, or permanent AF
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of nausea and vomiting requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: late evening leptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total dental anxiety (MDAS total score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anticipatory dental anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Energy intake during buffet meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes